CompletedNot Applicable

A Study of Flt3-Ligand Levels in Sjögrens Syndrome

Sweden30 participantsStarted 2009-06

Plain-language summary

The study aims to correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * fulfill the ACR-criteria for primary Sjogrens syndrome, * age above 18 years old Exclusion Criteria: * other CNS-disease

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This study measured Flt3-ligand levels in both cerebrospinal fluid and blood — does that mean a spinal tap was required, and is that a procedure you'd consider appropriate for my situation?
2Since this trial has already been completed, have the results been published, and if so, what did they find about the connection between Flt3-ligand and inflammation or nerve damage in Sjögren's syndrome?
3The study focused on primary Sjögren's syndrome specifically — how would you determine whether I have primary versus secondary Sjögren's, and does that distinction affect which research or treatments might apply to me?
4Because this was a biomarker study rather than a treatment trial, does it have any direct impact on my care right now, or is its value more about advancing future understanding of the disease?
5Are there currently any other studies or treatment trials for Sjögren's syndrome that build on this kind of inflammation and degeneration research that you think might be worth exploring for my case?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Correlate levels of Flt3-ligand in Cerebrospinal Fluid (CSF) and serum to markers for inflammation and degeneration in patients with primary Sjogrens syndrome

Timeframe: June 2009 - June 2015

Trial details

NCT IDNCT01470638

SponsorGöteborg University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-04

View on ClinicalTrials.gov More Sjogrens Syndrome trials